thymol on netrin-1 on obese patients

Conditions: Inflammatory Response; Obesity

Summary: the prevalence of obesity in mexico is 35.4%, and it is considered a risk factor for the development of diabetes, systemic arterial hypertension and dyslipidemia. obesity due to the increased distribution and growth of adipose tissue creates a pro-inflammatory state induced by molecules secreted by the adipocytes themselves. netrin-1 is a cell migration protein, which directs the recruitment, migration and entrapment of macrophages in different tissues, within adipose tissue the entrapment of macrophages induces the release of pro-inflammatory cytokines, which increase the secretion of pro-inflammatory adipokines. it has been found in high concentration in patients with obesity, insulin resistance and type 2 diabetes. thymol is a phytopharmaceutical derived from oregano oil that has shown powerful anti-inflammatory and antioxidant effects through the stimulation of ppar-gamma, adiponectin and inhibition of the nf-κb pathway mediated by the jnk pathway, pathways in which netrin-1 is involved in macrophage entrapment and recruitment.

objective: to evaluate the effect of thymol administration on the serum concentration of netrin-1 in obese subjects. material and methods: this is a randomized, double-blind, placebo-controlled clinical trial design. inclusion criteria: 1. - subjects between 18 and 35 years old. 2. - subjects with bmi ≥ 30.0 and ≤35.0. 3. - subjects with systolic blood pressure less than 135 mmhg. 4. - subjects with diastolic blood pressure less than 85 mmhg. 5. - voluntary acceptance and signing of the informed consent. these patients will be randomly assigned to two groups, one will have the intervention with thymol 200 mg every 8 hours for 90 days while the other will have placebo with mg 200 mg every 8 hours for 90 days. statistical analysis: quantitative variables: means and standard deviation. qualitative variables: frequencies and percentages. in the comparison according to the serum level of netrin-1 between the two groups after the intervention: t student for quantitative variables, chi square for qualitative variables. statistical significance p equal to or less than 0.05.

Eligibility criteria:
inclusion criteria: * subjects between 18 and 35 years old. * bmi ≥ 30.0 and ≤35.0 * systolic blood pressure less than 135 mmhg. * diastolic blood pressure less than 85 mmhg. exclusion criteria: * subjects who are known to have a diagnosis, receive treatment, or are observed with: * rheumatological and / or thyroid disease. * chronic kidney disease and / or ckd-epi glomerular filtration rate less than 60 ml / min / 1.72m2. * innate alterations of metabolism. * elevation of transaminases 2 times higher than normal. * total cholesterol greater than 250 mg / dl. * triglycerides greater than 300 mg / dl. * subjects presenting with acute illness, hospitalization, or drug treatment presented in the last 12 weeks prior to the study selection visit. * subjects with symptoms consistent with the definition of a probable case of covid-19, as well as any subject with a diagnosis of covid-19. * subjects who have had blood transfusions in the last 3 months. * regular smokers. * pregnant or lactating women. * women with a desire for pregnancy or who do not have a double barrier or progestin-only contraceptive method.

Keywords: netrin-1 thymol